Literature DB >> 16387569

Sexual dysfunction and cardiovascular disease: integrative concepts and strategies.

Kevin L Billups1.   

Abstract

The relation between erectile dysfunction (ED) and cardiovascular disease (CVD) is relevant and important to all fields of medicine. ED is often not considered in the same context as traditional cardiovascular conditions, such as hypertension, dyslipidemia, ischemic heart disease, diabetes mellitus, or the insulin resistance/metabolic syndrome complex. Specific guidelines for treating men with ED and known CVD have been established and recently updated. This article focuses on ED as an early symptom of systemic CVD as well as insulin resistance and the metabolic syndrome. The diagnosis of ED and the subsequent evaluation of underlying cardiovascular risk factors could become a powerful clinical tool to help with early detection of atherosclerotic disease and enhance overall preventive vascular health in men.

Entities:  

Mesh:

Year:  2005        PMID: 16387569     DOI: 10.1016/j.amjcard.2005.10.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.

Authors:  Thomas G Travison; Susan A Hall; William A Fisher; Andre B Araujo; Raymond C Rosen; John B McKinlay; Michael S Sand
Journal:  J Sex Med       Date:  2011-08-11       Impact factor: 3.802

2.  The Achilles heel of SPECT imaging: the false-positive scans--or are they?

Authors:  Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

3.  Usefulness of serum fetuin-A level as a marker of erectile dysfunction.

Authors:  W Kandeel; W El-Shaer; A Sebaey; A A Abou-Taleb; A Fathy; B Elmohamady; A I Mansour
Journal:  Int J Impot Res       Date:  2017-04-20       Impact factor: 2.896

4.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

5.  Sexual dysfunction in rheumatoid arthritis patients: arthritis and beyond.

Authors:  Y El Miedany; M El Gaafary; N El Aroussy; S Youssef; I Ahmed
Journal:  Clin Rheumatol       Date:  2011-11-24       Impact factor: 2.980

6.  Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?

Authors:  Andre B Araujo; Susan A Hall; Peter Ganz; Gretchen R Chiu; Raymond C Rosen; Varant Kupelian; Thomas G Travison; John B McKinlay
Journal:  J Am Coll Cardiol       Date:  2010-01-26       Impact factor: 24.094

7.  Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey.

Authors:  Shona C Fang; Raymond C Rosen; Joseph A Vita; Peter Ganz; Varant Kupelian
Journal:  J Sex Med       Date:  2014-10-08       Impact factor: 3.802

8.  Prostatic profile, premature ejaculation, erectile function and andropause in an at-risk Mexican population.

Authors:  J Jaspersen-Gastelum; J A Rodríguez; F J Espinosa de los Monteros; L Beas-Sandoval; José Guzmán-Esquivel; D D Calvo; T Gutiérrez
Journal:  Int Urol Nephrol       Date:  2008-07-15       Impact factor: 2.370

9.  Erectile dysfunction and mortality.

Authors:  Andre B Araujo; Thomas G Travison; Peter Ganz; Gretchen R Chiu; Varant Kupelian; Raymond C Rosen; Susan A Hall; John B McKinlay
Journal:  J Sex Med       Date:  2009-06-15       Impact factor: 3.802

Review 10.  A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Adv Urol       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.